Lung diseases such as Asthma and Chronic Obstructive Pulmonary Disease affect one in five people in the UK and kill someone every 5 minutes. The number of patients with these lung diseases was increasing in the NHS even before COVID-19. We are also learning about serious long-term effects of COVID-19 that will add to the existing burden on the NHS. There have been huge advances in technologies that allow scientists to see inside the lungs and measure what we breathe out. While this information has taught us quite a lot, it is still very difficult to combine different sources of information and turn it into new or improved treatments. Getting that useful information out of large amounts of medical test results requires sophisticated physics-based mathematical and statistical models run on powerful computers - a combination of techniques called data-driven biophysical multiscale modelling. The ability to develop those kinds of models will allow us to better understand how diseases start and how they progress. Our BIOREME network will support new research that uses these techniques to mimic biological and mechanical processes that occur throughout the lung. Using the information from thousands of lung tests, the idea is then to get these models to mimic real diseased lungs. In order to improve and build trust in these models, some of our projects will be focused on comparing their outputs to results from other lung tests. Medical scientists can then use such models to test what might happen in a particular type of lung disease, and to investigate possible responses to new treatments before testing these in patients. Most importantly, this will lead to the design of new drugs and improved trials for new treatments. The first step will be to get medics, imaging experts and mathematicians together with industry and patient group representatives to decide on which specific research areas to prioritise, where this form of modelling will make the most difference. This NetworkPlus award will then allow us to organise multiple events, in different formats, designed to help researchers to collaborate, and to come up with the best initial projects to help achieve our goals. We will then help the researchers to develop these into larger projects that will attract funding from other sources and continue the research into the future. Even after this funding runs out, BIOREME will provide a lively forum for lung researchers to continue solving problems using these advanced computational tools. Finally, BIOREME will support outreach activities to engage and educate communities and young people in the role that mathematics can play in medicine and healthcare, and to inspire a new generation of respiratory scientists from diverse backgrounds.

A drug is a molecule that acts upon biological processes in the body. In contrast, a medicine is a complex product that comprises the drug and other ingredients packaged into a final dosage form that can be administered to a patient to ensure there is a beneficial therapeutic effect with minimum side-effects. To achieve therapeutic effect it is essential to ensure that the drug is delivered to the appropriate site in the body, at the right time, and in the correct amount. This is challenging: some drug molecules are poorly soluble in biological milieu, while others are either not stable or have toxic side-effects and require careful processing into medicines to ensure they remain biologically active and safe. The new drug molecules arising from drug discovery and biotechnology have particularly challenging properties. Pharmaceutical technologies are central to developing medicines from these molecules, to ensure patients are provided with safe and efficacious therapy. The design and development of new medicines is an inherently complex and cross-disciplinary process, and requires both innovative research and highly skilled, imaginative, researchers. To sustain and reinforce the UK's future global competitiveness, a new generation of highly-trained graduates educated at doctoral level is required to deliver transformative new therapeutics. Our CDT will train an empowered network of at least 60 PhD students through a consortium of multiple industry partners led by the University of Nottingham and University College London. The involvement of partners from start-ups to major international pharmaceutical companies will ensure that our students receive the cross-disciplinary scientific knowledge needed to develop future medicines, and build the leadership, resilience and entrepreneurial skills crucial to allow them to function effectively as future leaders and agents of change. Through partnering with industry we will ensure that the research work undertaken in the CDT is of direct relevance to contemporary and future challenges in medicines development. This will allow the CDT research to make significant contributions to the development of new therapies, leading ultimately to transformative medicines to treat patients. Beyond the research undertaken in the CDT, our graduates will build careers across the pharmaceutical and healthcare sector, and will in the future impact society through developing new medicines to improve the health and well-being of individuals across the world. We will train our students in four key science themes: (i) predictive pharmaceutical sciences; (ii) advanced product design; (iii) pharmaceutical process engineering; and, (iv) complex product characterisation. This will ensure our graduates are educated to approach challenges in preparing medicines from a range of therapeutic molecules, including emerging cutting-edge actives (e.g. CRISPR, or locked RNAs). These are currently at a critical stage of development, where research by scientists trained to doctoral level in the latest predictive and product design and development technologies is crucial to realise their clinical potential. Our students will obtain comprehensive training in all aspects of medicines design and development, including pharmaceutical engineering, which will ensure that they consider early the 'end game' of their research and understand how their work in the laboratory can be translated into products which can be manufactured and enter the clinic to treat patients.